Annual Meeting of the American Thyroid Association | Conference

Dr. Brose Discusses Lenvatinib and Sorafenib in Differentiated Thyroid Cancer

November 2nd 2014

Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center at the University of Pennsylvania, discusses the rapidly changing treatment landscape for patients with differentiated thyroid cancer.

Dr. Sosa Discusses Molecular Testing in Thyroid Cancer

November 2nd 2014

Julie A. Sosa, MD, MS, professor of surgery and medicine, chief of endocrine surgery, Duke University, discusses molecular testing for thyroid cancer.

Novel NGS Test May Enhance Diagnosis and Management of Indeterminate Thyroid Nodules

November 2nd 2014

A next-generation sequencing assay has shown promise as a new tool to aid in the diagnosis and treatment of indeterminate thyroid nodules.

Next-Generation Sequencing Effectively Detects Cancer in Thyroid Nodules

November 2nd 2014

The ThyroSeq v2 next-generation sequencing assay was highly accurate at diagnosing cancer in thyroid nodules with follicular neoplasm or those suspected of follicular neoplasm cytology.

Vitamin D Levels Predict Hypocalcemia After Thyroid Cancer Treatment

November 1st 2014

Preoperative vitamin D deficiency is associated with postoperative symptomatic hypocalcemia in patients with thyroid cancer undergoing total thyroidectomy plus central compartment neck dissection.

Novel Therapeutic Target Identified in Aggressive Thyroid Cancers

November 1st 2014

In vivo models for two aggressive thyroid cancers have shown that downregulation of miR-30a-5p leads to overexpression of LOX, a target which appears amenable to treatment with β-aminopropionitrile fumarate.

New Assay Effectively Detects Circulating BRAFV600E in Patients With Papillary Thyroid Cancer

November 1st 2014

The detection of BRAFV600E in patients with papillary thyroid cancer using a blood-based assay was shown to be feasible in a cohort of patients undergoing thyroidectomy.

Dr. Ganly on a Postoperative Nomogram for Predicting Cancer-Specific Mortality in MTC

November 1st 2014

Ian Ganly, MD, PhD, from Memorial Sloan Kettering Cancer Center, discusses the development of a postoperative nomogram for predicting cancer-specific mortality in MTC.

Dr. Bible Discusses the Promise of Pemetrexed in Follicular Thyroid Cancers

November 1st 2014

Keith C. Bible, MD, PhD, professor of oncology, Mayo Clinic, discusses the promise of pemetrexed and carboplatin as a potential treatment option for patients with follicular cell-derived thyroid cancers.

ATA Highlights New Thyroid Cancer Research

October 31st 2014

The impact of RAI on long-term outcomes, potential combination strategies, molecular profiling, and novel therapeutics for patients with thyroid cancer were among some of the topics highlighted at the 2014 ATA Annual Meeting.

Dr. Busaidy on the Association Between THST and Improved Outcomes

October 31st 2014

Naifa L. Busaidy, MD, associate professor, MD Anderson Cancer Center, discusses the results of a cooperative study that investigated the association between long-term thyroid hormone suppression therapy and improved outcomes in patients.

Moderate THST Improves Outcomes in Differentiated Thyroid Cancer

October 31st 2014

Long-term moderate thyroid hormone suppression therapy is associated with improved outcomes in patients with differentiated thyroid cancer.

Dr. Nucera Discusses the Role of RNA in Thyroid Cancer

October 31st 2014

Carmelo Nucera, MD, PhD, endocrinologist, assistant professor, Harvard Medical School, Division of Experimental Pathology, Beth Israel Deaconesss Medical Center, Boston, discusses the role of RNA in thyroid cancer

Disease-Related Variables Predictive of Outcomes With Sorafenib in DTC

October 31st 2014

Numerous disease-related variables could serve as prognostic and predictive factors for treatment outcomes with sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer.

Dr. Dadu on Reducing MTC-Related Diarrhea With CASAD

October 31st 2014

Ramona Dadu, MD, from the MD Anderson Cancer Center, discusses the results of a pilot study that examined the efficacy of CASAD, a natural clay, to reduce medullary thyroid cancer-related diarrhea.

PD-1 Immunotherapies Induce Painless Thyroiditis in Patients With Metastatic Malignancies

October 31st 2014

Treatment with PD-1 immunotherapy across various oncology clinical trials has been associated with the induction of painless thyroiditis, characterized by transient thyrotoxicosis and hypothyroidism, in patients with metastatic malignancies

Dr. Cohen Discusses the Challenges of Treating Medullary Thyroid Cancer

October 30th 2014

Ezra Cohen, MD, professor of medicine, UC San Diego Moores Cancer Center, discusses the challenges of treating Medullary Thyroid Cancer (MTC).

Molecular Diagnostics Focus on Thyroid Nodule Classification

October 30th 2014

New data being presented at the 84th Annual Meeting of the American Thyroid Association show promise for two molecular tests that help identify indeterminate thyroid nodules as either benign or malignant.

Dr. Sherman Discusses MEK Inhibitors for Thyroid Cancer

October 22nd 2012

Steven I. Sherman, MD, from MD Anderson Cancer Center, discusses the clinical interest in MEK inhibitors for thyroid cancer and a broad range of other tumors that signal through the MAP kinase pathway.

Dr. Sippel Explains Thyroid Cancer Risk Factors

October 2nd 2012

Rebecca S. Sippel, MD, from University of Wisconsin, explains the need for added screening for those at high-risk of developing thyroid cancer.

Multikinase Inhibitor Prolongs Progression-Free Survival in MTC

September 25th 2012

Cabozantinib significantly prolonged progression-free survival in medullary thyroid cancer compared with placebo among patients with radiographically confirmed progressive disease at study onset.

Photos From the American Thyroid Association Annual Meeting

September 25th 2012

Photos from the 82nd Annual Meeting of the American Thyroid Association held in Quebec City, Canada, on September 19-23, 2012.

Dr. Sippel on the Importance of the Initial Surgery for MTC

September 25th 2012

Rebecca S. Sippel, MD, from the University of Wisconsin, discusses the importance of the initial surgery for patients with medullary thyroid cancer on outcomes.

Panels of Molecular Markers Improve Diagnosis of Thyroid Cancer

September 24th 2012

The application of molecular markers is already significantly improving the diagnosis of thyroid cancer and broader application could help prevent unnecessary surgeries to confirm the diagnosis.

BRAF Mutational Status in Papillary Microcarcinoma: Diagnostic and Prognostic Potential

September 24th 2012

Four histopathologic features of papillary microcarcinoma help predict how aggressive the tumor will be and subsequently how aggressive treatment must be to prevent its spread.

Dr. Haugen Describes the 82nd Annual ATA Meeting

September 21st 2012

Dr. Bryan Haugen, from University of Colorado School of Medicine, Describes the 82nd Annual Meeting of the American Thyroid Association.

Dr. Nikiforov on Molecular Testing of Thyroid Nodules

September 21st 2012

Dr. Yuri Nikiforov, from the University of Pittsburgh, on Molecular Testing to Diagnose Cancerous Thyroid Nodules.

Blanket Approach to RAI in PTC Patients May Not Be Necessary

September 21st 2012

A blanket approach to the use of radioactive iodine may not be necessary in many patients with papillary thyroid cancer provided they undergo expert total thyroidectomy first.

Disease Stabilization Now Possible in Metastatic MTC With Targeted Therapies

September 21st 2012

The availability of molecular agents that target oncogenic signaling pathways now offers the possibility of achieving disease stabilization in a proportion of patients with metastatic medullary thyroid cancer.

Initial Operation to Remove Medullary Thyroid Cancer Best Chance for Cure

September 21st 2012

The initial surgical procedure performed for the management of medullary thyroid cancer is the best chance surgeons have for a cure.